ATE315934T1 - Thrombopoietin-mimetika - Google Patents

Thrombopoietin-mimetika

Info

Publication number
ATE315934T1
ATE315934T1 AT00961674T AT00961674T ATE315934T1 AT E315934 T1 ATE315934 T1 AT E315934T1 AT 00961674 T AT00961674 T AT 00961674T AT 00961674 T AT00961674 T AT 00961674T AT E315934 T1 ATE315934 T1 AT E315934T1
Authority
AT
Austria
Prior art keywords
mammal
invented
thrombopoietin mimetics
mimetics
thrombopoietin
Prior art date
Application number
AT00961674T
Other languages
English (en)
Inventor
Juan I Luengo
Kevin J Duffy
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Application granted granted Critical
Publication of ATE315934T1 publication Critical patent/ATE315934T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/44—Oxygen and nitrogen or sulfur and nitrogen atoms
    • C07D231/46—Oxygen atom in position 3 or 5 and nitrogen atom in position 4
    • C07D231/48—Oxygen atom in position 3 or 5 and nitrogen atom in position 4 with hydrocarbon radicals attached to said nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT00961674T 1999-09-10 2000-09-08 Thrombopoietin-mimetika ATE315934T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US15335899P 1999-09-10 1999-09-10
US20366800P 2000-05-12 2000-05-12

Publications (1)

Publication Number Publication Date
ATE315934T1 true ATE315934T1 (de) 2006-02-15

Family

ID=26850465

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00961674T ATE315934T1 (de) 1999-09-10 2000-09-08 Thrombopoietin-mimetika

Country Status (7)

Country Link
EP (1) EP1213965B1 (de)
JP (1) JP4488663B2 (de)
AT (1) ATE315934T1 (de)
AU (1) AU770564B2 (de)
DE (1) DE60025632T2 (de)
ES (1) ES2256038T3 (de)
WO (1) WO2001017349A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CY2010012I2 (el) * 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
JP3966816B2 (ja) 2000-05-30 2007-08-29 中外製薬株式会社 トロンボポエチン様活性を有する化合物
WO2002085343A1 (en) * 2001-03-01 2002-10-31 Smithkline Beecham Corporation Thrombopoietin mimetics
AR040083A1 (es) 2002-05-22 2005-03-16 Smithkline Beecham Corp Compuesto bis-(monoetanolamina) del acido 3'-[(2z)-[1-(3,4-dimetilfenil) -1,5-dihidro-3-metil-5-oxo-4h-pirazol-4-iliden] hidrazino] -2'-hidroxi-[1,1'-bifenil]-3-carboxilico, procedimiento para prepararlo, composicion farmaceutica que lo comprende, procedimiento para preparar dicha composicion farmac
EP1552828A4 (de) 2002-08-14 2007-01-24 Nissan Chemical Ind Ltd Thrombopoetin-rezeptor-aktivator und verfahren zu seiner herstellung
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
WO2005118551A2 (en) * 2004-05-28 2005-12-15 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
MX2007004765A (es) 2004-10-25 2007-07-09 Ligand Pharm Inc Compuestos y metodos que modulan la actividad de la trombopoyetina.
AU2005312585B2 (en) 2004-12-08 2012-01-12 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
JP4973192B2 (ja) 2004-12-14 2012-07-11 日産化学工業株式会社 アミド化合物及びトロンボポエチンレセプター活性化剤
JP5071375B2 (ja) 2005-07-15 2012-11-14 日産化学工業株式会社 チオフェン化合物及びトロンボポエチンレセプター活性化剤
KR101290484B1 (ko) 2005-07-20 2013-07-26 닛산 가가쿠 고교 가부시키 가이샤 피라졸 화합물 및 트롬보포이에틴 수용체 활성화제
CA2619262A1 (en) * 2005-08-19 2007-02-22 Astrazeneca Ab Pyrazolone derivatives for the treatment of tuberculosis
JP5205967B2 (ja) 2005-11-07 2013-06-05 日産化学工業株式会社 ヒドラジド化合物及びトロンボポエチンレセプター活性化剤
WO2007062078A2 (en) * 2005-11-23 2007-05-31 Ligand Pharmaceuticals Inc. Thrombopoietin activity modulating compounds and methods
US8093251B2 (en) 2006-06-07 2012-01-10 Nissan Chemical Industries, Ltd. Nitrogen-containing heterocyclic compounds and thrombopoietin receptor activators
WO2008070583A2 (en) 2006-12-01 2008-06-12 Stategics, Inc. Thrombopoietin mimetics
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
CN101481352A (zh) 2008-01-10 2009-07-15 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物、其制备方法及其在医药上的应用
PE20100362A1 (es) 2008-10-30 2010-05-27 Irm Llc Derivados de purina que expanden las celulas madre hematopoyeticas
SG176088A1 (en) 2009-05-29 2011-12-29 Glaxosmithkline Llc Methods of administration of thrombopoietin agonist compounds
CN101921232A (zh) 2009-06-11 2010-12-22 上海恒瑞医药有限公司 双环取代吡唑酮偶氮类衍生物的盐,其制备方法及其在医药上的应用
WO2012102937A2 (en) 2011-01-25 2012-08-02 Irm Llc Compounds that expand hematopoietic stem cells
EP2788476B1 (de) 2011-12-08 2019-05-22 Fred Hutchinson Cancer Research Center Zusammensetzungen und verfahren zur erhöhten erzeugung von hämatopoietischen stamm-/vorläuferzellen
RS59002B1 (sr) 2012-01-27 2019-08-30 Univ Montreal Pirimido[4,5-b]indol derivati i njihova primena u ekspanziji hematopoetskih matičnih ćelija
CN103232729A (zh) * 2013-01-10 2013-08-07 浙江山峪染料化工有限公司 多组份拼混型分散黄染料配方
CN103232728B (zh) * 2013-01-10 2014-08-20 浙江山峪染料化工有限公司 混拼型分散黄染料
CN103232727B (zh) * 2013-01-10 2014-09-03 浙江山峪染料化工有限公司 一种多组份拼混型分散黄染料
CN103232730B (zh) * 2013-01-10 2015-01-14 浙江山峪染料化工有限公司 一种混拼型分散黄染料
CN103044968B (zh) * 2013-01-11 2014-10-22 浙江山峪染料化工有限公司 一种分散黄染料
EP3134409B1 (de) 2014-04-22 2020-02-12 Université de Montréal Verbindungen und verwendung davon in der expansion von hämatopoietischen stammzellen und/oder hämatopoietischen vorläuferzellen
JP6658535B2 (ja) 2014-10-31 2020-03-04 日産化学株式会社 リガンド結合繊維及び当該繊維を用いた細胞培養基材
EP3886854A4 (de) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrol- und pyrazolverbindungen und verfahren zu deren verwendung

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5482546A (en) * 1994-03-30 1996-01-09 Canon Kabushiki Kaisha Dye, ink containing the same, and ink-jet recording method and instrument using the ink
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics

Also Published As

Publication number Publication date
JP4488663B2 (ja) 2010-06-23
EP1213965A4 (de) 2003-05-02
JP2003508463A (ja) 2003-03-04
EP1213965A1 (de) 2002-06-19
WO2001017349A1 (en) 2001-03-15
DE60025632D1 (de) 2006-04-06
ES2256038T3 (es) 2006-07-16
AU7359400A (en) 2001-04-10
AU770564B2 (en) 2004-02-26
DE60025632T2 (de) 2006-08-10
EP1213965B1 (de) 2006-01-18

Similar Documents

Publication Publication Date Title
ATE350044T1 (de) Thrombopoietinmimetika
DE60025632D1 (de) Thrombopoietin-mimetika
ATE344031T1 (de) Thrombopoietin-mimetika
MY136707A (en) Thrombopoietin mimetics
WO2002049413A3 (en) Thrombopoietin mimetics
HK1043472A1 (zh) 血小板减少症拟态
WO2004054515A3 (en) Thrombopoietin mimetics
EP1133291A4 (de) Verfahren zur behandlung der thrombozytopenie
CY1108221T1 (el) Μεθοδος για την αναπαραγωγη πλευρομουτιλινων
DE60124684D1 (de) Sulfonamido-substituierte verbrückte bicycloalkylderivative
ATE254461T1 (de) Behandlung von augenschmerzen
EP1610778A4 (de) Behandlung von benigner prostatahyperplasie
ATE203519T1 (de) Chinolinderivate als antimalariamittel
ATE516027T1 (de) Orazamid orotat zur vorbeugung von leberschäden
EP1117431A4 (de) Behandlung von acidose
EP1441761A4 (de) Verfahren zur prävention und behandlung von infektionen mit dem flavivirus bei tieren
DE60103685D1 (de) Behandlung von Poriomania
DE60110748D1 (de) Behandlung von fluorkohlenstoff-beschickungen
CY1106363T1 (el) Χρηση του ενepγοποιημενου παραγοντα πηξης vii για την αγωγη των επαγομενων απο θρομβολυτικη θepαπεια μειζονων αιμορραγιων
ATE302008T1 (de) Behandlung von entzündlichen erkrankungen
EA200100785A1 (ru) Шипучие слабительные средства
TR200003084T2 (tr) Paroxetine askorbat
DE60125035D1 (de) Behandlung von plasmid-haltigen lösungen
LU91009B1 (de) Behandlung von Verbrennungen
ATE294590T1 (de) Verwendung von interleukin-11 zur behandlung von hämoragischem schock

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties